Esperion Therapeutics Slides 7% Despite New Liver Disease Pipeline Announcement
Esperion Therapeutics, Inc. (ESPR) declined 7.36% midday, weighing on the PRISM Emerging Global Health Index, following an R&D Day presentation where the company unveiled a new development program targeting Primary Sclerosing Cholangitis (PSC)—a rare, chronic liver disease with no approved therapies.
The program centers on Esperion’s next-generation allosteric ACLY inhibitors, with lead candidate ESP-1336 showing encouraging preclinical results. Studies demonstrated reduced liver inflammation, injury, and fibrosis across multiple PSC models. The company is aiming to leverage its ACLY biology expertise—previously applied in cardiovascular drug development—to expand into hepatic diseases, where it estimates a market opportunity exceeding $1 billion.
CEO Sheldon Koenig emphasized the unmet need in PSC and the company’s commitment to addressing it, stating, “Our lead candidates represent a natural extension of our metabolic franchise.”
EDAP TMS Rises 7% Ahead of New Robotic HIFU System Launch at Major Urology Event
EDAP TMS SA (EDAP) climbed 7.36%, pushing the PRISM Emerging MedDevices Index higher, following its announcement that it will debut the new Focal One® i Robotic HIFU system at the American Urological Association’s (AUA) Annual Meeting later this week.
The upgraded platform includes major enhancements in imaging compatibility—now integrating PSMA PET, ExactVu™ Micro-Ultrasound, and AI-powered guidance via Unfold AI™ and OnQ™ Prostate. Designed with surgeon feedback in mind, Focal One i supports remote proctoring, treatment recording, and collaborative procedures. EDAP’s CEO Ryan Rhodes noted the system is tailored to meet the future needs of urologists and elevate training and patient access globally.
Other PRISM Mid-Day Movers:
The post PRISM Mid-Day Movers: Global Health and MedDevices Diverge Despite Broader Market Gains appeared first on PRISM MarketView.